Cadila Healthcare gets USFDA nod for metronidazole tablets
Chennai : Pharma major Cadila Healthcare Ltd. said it has received the final approval from the US Food and Drug Administration (USFDA) to market metronidazole tablets.
In a regulatory filing with BSE, Cadila Healthcare said it has got USFDA's approval to market metronidazole in strengths 250 mg and 500 mg tablets.
The drug is used to treat infections caused by bacteria or parasites.
According to Cadila Healthcare, the tablets will be made at the group's formulations manufacturing facility at Baddi in Himachal Pradesh.
The company said the group now has more than 105 approvals and has so far filed nearly 275 ANDAs (Abbreviated New Drug Application) since the commencement of the filing process in FY 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd